Podcasts about clinical trials

Neuraxial analgesia (epidural or spinal) combined withtocolytic therapy is the pain control method that best increases the success rate of external cephalic version (ECV), according to the ACOG's PB 221. However, some patients may be reluctant to use regional anesthesia and may askabout IV analgesia. A new study in the AJOG (released as an ePub on March 5, 2026) provides some insights that may be helpful for patient consultation. These investigators compared the success of external cephalic version, modes of delivery, maternal pain, and complications using three strategies: intravenous analgesia with remifentanil, epidural anesthesia, and a stepwise approach in which epidural anesthesia was administered only if intravenous analgesia was unsuccessful. Listen in for details.1.     ACOG PB 2212.     Aiartzaguena, Amaia et al. Comparativeeffectiveness of intravenous remifentanil, epidural anesthesia and a two-stepanalgesic approach for external cephalic version: a large prospectivesingle-center cohort study. American Journal of Obstetrics & Gynecology,Volume 0, Issue 03.     Hao Q, Hu Y, Zhang L, et a l. A SystematicReview and Meta-Analysis of Clinical Trials of Neuraxial, Intravenous, andInhalational Anesthesia for External Cephalic Version. Anesthesia andAnalgesia. 2020. 4.     Wilson MJA, MacArthur C, Hewitt CA, et al.5.     Intravenous Remifentanil Patient-ControlledAnalgesia Versus Intramuscular Pethidine for Pain Relief in Labour (RESPITE):An Open-Label, Multicentre, Randomised Controlled Trial. Lancet. 2018.

Robotic pets make life easier for patients with dementia; Risks, benefits of “natural” ED formulas; Sorting out those pricey new injectable osteoporosis drugs; Daily multivitamin delays biological aging; Study challenges notion that aging means inevitable decline; Breastfeeding confers weight loss benefits—to moms; Can you avoid a colonoscopy with a new colon cancer blood test? Color blindness may hide warning signs of cancer.

Episode Notes Complicated UTIs just got a whole lot less complicated—or did they? Dr. Dana Bowers and Kyle Molina (@kcmolinaID) join Dr. Whitney Buckel to break down what's new, what's controversial, and what this means for your day‑to‑day antimicrobial decisions. Join us as we dig into the biggest updates, the evidence behind them, and the clinical pearls you won't want to miss. References: Nelson Z, Aslan AT, Beahm NP, et al. Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: A WikiGuidelines Group Consensus Statement. JAMA Netw Open. 2024 Nov 4;7(11):e2444495. Trautner BW, Cortes-Penfield NW, Gupta K, et al. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. Published July 17, 2025. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/ Kadry N, Natarajan M, Bein E, Kim P, Farley J. Discordant Clinical and Microbiological Outcomes Are Associated With Late Clinical Relapse in Clinical Trials for Complicated Urinary Tract Infections. Clin Infect Dis 2023;76(10:1768-1775. https://academic.oup.com/cid/article/76/10/1768/6980780 USCAST Oral cephalosporin STIC against S. aureus and E. coli meeting recording. https://www.youtube.com/watch?v=HieaVFAC08s MacDougall C. A Cloudy Crystal Ball: Critically Assessing and Rethinking the Antibiogram. Clin Infect Dis. 2023;77(11):1501-1503. doi:10.1093/cid/ciad468 Koehl J, Spolsdoff D, Negaard B, et al. Cephalosporins for Outpatient Pyelonephritis in the Emergency Department: COPY-ED Study. Ann Emerg Med. 2025;85(3):240-248. doi:10.1016/j.annemergmed.2024.10.013 Dunne MW, Aronin SI, Das AF, et al. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clin Infect Dis. 2023;76(1):78-88. doi:10.1093/cid/ciac704 Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/)https://www.instagram.com/breakpointspodcast_sidp/?hl=en Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

For people living with kidney disease, clinical trials can offer hope—but not without questions or concerns. Today, we talk with Dr. Nadine Barrett, Glenda Roberts, and Luz Baqueiro about lived experience, community trust, and the power of being asked. In this episode we heard from:  Dr. Nadine J. Barrett is a Professor in the Department of Social Sciences and Health Policy in the Division of Public Health Sciences and the inaugural Senior Associate Dean of Community Engagement and Equity in Research at Wake Forest School of Medicine, she is Associate Director of Community Outreach and Engagement for Wake Forest Comprehensive Cancer Center, the Clinical Translational Science Institute and the Maya Angelou Center for Health Equity. Prior to joining Wake Forest, Dr. Barrett served 13 years in senior leadership roles at Duke University, as the Founding Director of both the Duke Center for Equity in Research and the nationally awarded, Duke Cancer Institute's Office of Health Equity. She is also President of the national Association of Cancer Care Centers, in Washington DC. A medical sociologist by training, Dr. Barrett is a health disparities researcher, expert equity strategist, and a nationally recognized leader in facilitating authentic community, healthcare, and academic partnerships to advance health equity. She develops multi-level interventions to address implicit bias, structural and systemic racism, and inequities that limit access to quality research and trustworthy health care among underserved and marginalized populations. Dr. Barrett brings an equity lens to her work and collaborations to enhance healthcare systems, close the disparities gap in health outcomes, and increase diverse and broad representation in research participation and the research workforce. Glenda Roberts: Prior to joining the Mount Sinai Center for Kidney Disease Innovation as the Director of Communications and Patient Engagement, Glenda V. Roberts was an Information Technology executive with over 35 years of experience with top-caliber corporations, including General Electric, Microsoft and Johnson & Johnson. She was also the Executive Director of the Seattle Transplant House, and the Director of External Relations & Patient Engagement at the University of Washington Center for Dialysis Innovation (CDI) and the Kidney Research Institute (KRI). Before going on dialysis, Glenda managed the progression of her disease for over 40 years using diet and exercise. Since her transplant in 2010, she's completed nine half marathons. Based upon her personal experience with kidney disease, Glenda is a passionate activist for kidney research and patients living with kidney disease. She's involved in myriad patient-centered national and international health care transformation initiatives.  All are focused on addressing patient preferences and improving patient-reported outcomes.   Glenda brings the patient voice to several NIH/NIDDK government and industry research efforts (Kidney Precision Medicine Project, APOLLO), as well as the American Society of Nephrology's Current & Emerging Threats (C-ET) Steering Committee. She's the inaugural co-chair of the Critical Path Institute's Biomarker Data Repository Governance Committee, and a member of the Kidney Health Initiative (KHI) Board of Directors. Additionally, she contributes to the Advisory Boards of LifeCenter Northwest and Home Dialyzors United, and over 15 other industry and academic research advisory committees/boards focused on transplantation, kidney, cardiovascular, and metabolic health. As an ambassador for the National Kidney Foundation, the American Kidney Fund, and the American Association of Kidney Patients, Glenda's advocacy tirelessly advances the voices, needs, and aspirations of the kidney community worldwide. Luz Baqueiro serves as a patient advocate with the National Kidney Foundation (NKF), providing feedback and helping develop new initiatives to better support the Latin American community affected by chronic kidney disease. She also raises awareness of the barriers faced by patients living with renal failure while educating and supporting her community in Georgia. In 2019, Luz was diagnosed with end-stage renal disease (ESRD). With limited resources  in Georgia, she relied on emergency in-hospital dialysis for a year. In August 2021, through self-determination, self-education, and the support of her family and community, she received a kidney transplant.   Additional Resources Clinical Trial Information Hub What is a Clinical Trial? Are Clinical Trials Safe?   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Epidemiologist Yvonne “Bonnie” Maldonado is an expert in vaccine research and public health. Look back centuries, and the story is always the same, she says: Death rates from viruses have plummeted, especially in children and the elderly. And yet, millions of children die each year from vaccine-preventable diseases. Vaccines need a return of public confidence, and that starts with better messaging and greater support of nongovernmental messengers like herself. The bottom line is that vaccines are safe, she says. Vaccines work and we have saved many lives because of them, Maldonado reminds host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Yvonne Maldonado Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Yvonne “Bonnie” Maldonado, a professor of pediatrics, epidemiology and population health at Stanford University. (00:03:01) Career in Vaccines Bonnie shares what led to her career in vaccine research. (00:04:53) How Vaccines Work How vaccines train the immune system to recognize and fight pathogens. (00:06:46) Why Vaccine Responses Vary The variability in immune responses and breakthrough infections. (00:09:22) Risk vs. Benefit in Vaccines How researchers evaluate side effects versus disease severity. (00:11:53) How Viruses Evolve The evolutionary dynamics that shape viral behavior. (00:13:59) Vaccine Boosters Why some vaccines last for life while others require multiple doses. (00:17:14) Herd Immunity How community protection works and why vaccination rates matter. (00:21:22) Vaccine Controversy The controversy surrounding vaccines and what led to it. (00:24:27) Global Vaccine Hesitancy How declining trust and past outbreaks influence vaccination globally. (00:27:07) The Future of Vaccines Why vaccines are essential and how outbreaks shape public response. (00:29:08) Preparing for Future Pandemics How healthcare systems prepare for new threats after COVID-19. (00:30:43) Future In a Minute Rapid-fire Q&A: hope, public trust, and the future of health. (00:32:54) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Science likes to call itself a meritocracy. Angela Anderson and Brandi Mattson know better. Both served as editors at elite journals (Cell and Neuron), where a single decision could determine who gets tenure, funding, or obscurity. They watched brilliant data get filtered out because the authors did not know the unwritten rules controlled by 5 dominant publishing houses with profit margins higher than Google.In 2020, amid pandemic shutdowns and national reckoning over racial injustice, they co-founded a nonprofit to expose that hidden curriculum. Through the JEDI program, they provide 10 hours of free editorial consulting to scientists who lack access to elite networks. In 1 year alone, 25 awards helped researchers salvage canceled grants, secure NSF career funding, and rebuild careers derailed by rejection.This episode pulls back the curtain on the multibillion dollar publishing engine that profits from taxpayer funded science and reveals who gets heard, who gets sidelined, and how insiders are choosing to redistribute power.RELATED LINKSAngela AndersonBrandy MattsonLife Science EditorsLife Science Editors FoundationCellNeuronNational Science FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send a textWhat do the latest findings from the 2025 San Antonio Breast Cancer Symposium mean for people living with metastatic breast cancer? In this episode, Dr. Bora Lim of MD Anderson Cancer Center joins us to break down the most impactful research and clinical trial updates from SABCS 2025. Together we will explore advances in hormone receptor positive, HER2-positive disease and triple negative disease and discuss how these updates may influence treatment decisions right now. We also wrap up with an audience Q&A, including questions about GLP-1 medications.Listen in for expert insight, practical takeaways, and clarity on the evolving MBC treatment landscape.

Welcome to OncLive On Air®! I'm your host today, Kyle Doherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, we spoke with Sonali Smith, MD. Dr Smith holds the Elwood V. Jensen Professorship of Medicine and is the chief of the Section of Hematology/Oncology at UChicago Medicine. In our exclusive interview, Dr Smith discussed CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults. _____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Send a textDr. Michael Koren and Dr. Ravi Pande present What You Should Know about Strokes, including how high cholesterol and blood pressure can increase your risk. In this episode, recorded in front of a live audience, the two doctors discuss the BE FAST warning signs of a stroke and the importance of getting to an emergency room as fast as possible. Then they talk about treatment options, including new medications and guidelines that guide how doctors may use medications or rapid surgery to help preserve brain cells. Finally, the doctors emphasize the importance of prevention and how keeping blood pressure and cholesterol under control has measurable, positive impacts on stroke risk and recovery.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Tyrone Lam, is Chief Business Development Officer at GATC Health, a company that has developed a predictive AI model to derisk and accelerate drug discovery and development. A significant partnership with Lloyd's of London to use this technology to underwrite insurance for clinical trials enables the insurer to base financing decisions on objective reports that predict a drug's safety and efficacy with high accuracy. There is potential for this technology to become a standard for biotech investment, reducing reliance on animal testing and enabling more efficient development of drugs for smaller patient populations.  Tyrone explains, "GATC Health is a technology company that is de-risking and accelerating the drug discovery and drug development process. So at a higher level, our mission is to take as much of the financial and scientific risk out of the drug discovery business as possible, which would enable better, safer, and more available drugs to be available for humans."   "Our overall platform is called Operon that has literally hundreds of AI models built in that basically do three things. One is that we're able to discover and validate in silico the targets in the body associated with a particular disease. And then the second piece of our platform broadly is the ability to generate novel compounds to treat those diseases. And then we created off of Operon an independent validation that would run in silico, like an AI-generated clinical trial to understand how those novel drugs would perform against those targets in human physiology."   "That third part of the platform is where we created a product called Derisq, and that is an independent, objective report that we can run on other people's drugs, biotech pharma's drug candidates, to give them a very rapid indication of how that drug's going to perform in a human clinical trial."  #GATCHealth #DrugDiscovery #AIinHealthcare #PharmaInnovation #ClinicalTrials #HealthTech #MedicalAI #Biotechnology #PrecisionMedicine #HealthcareInnovation #FutureOfMedicine #DrugDevelopment #AIplatform #DueDiligence  #DeriskingBiotech #Derisq #CapitalEfficiency #RiskIntelligence #BiotechInvesting  GATCHealth.com Listen to the podcast here

Tyrone Lam, is Chief Business Development Officer at GATC Health, a company that has developed a predictive AI model to derisk and accelerate drug discovery and development. A significant partnership with Lloyd's of London to use this technology to underwrite insurance for clinical trials enables the insurer to base financing decisions on objective reports that predict a drug's safety and efficacy with high accuracy. There is potential for this technology to become a standard for biotech investment, reducing reliance on animal testing and enabling more efficient development of drugs for smaller patient populations.  Tyrone explains, "GATC Health is a technology company that is de-risking and accelerating the drug discovery and drug development process. So at a higher level, our mission is to take as much of the financial and scientific risk out of the drug discovery business as possible, which would enable better, safer, and more available drugs to be available for humans."   "Our overall platform is called Operon that has literally hundreds of AI models built in that basically do three things. One is that we're able to discover and validate in silico the targets in the body associated with a particular disease. And then the second piece of our platform broadly is the ability to generate novel compounds to treat those diseases. And then we created off of Operon an independent validation that would run in silico, like an AI-generated clinical trial to understand how those novel drugs would perform against those targets in human physiology."   "That third part of the platform is where we created a product called Derisq, and that is an independent, objective report that we can run on other people's drugs, biotech pharma's drug candidates, to give them a very rapid indication of how that drug's going to perform in a human clinical trial."  #GATCHealth #DrugDiscovery #AIinHealthcare #PharmaInnovation #ClinicalTrials #HealthTech #MedicalAI #Biotechnology #PrecisionMedicine #HealthcareInnovation #FutureOfMedicine #DrugDevelopment #AIplatform #DueDiligence  #DeriskingBiotech #Derisq #CapitalEfficiency #RiskIntelligence #BiotechInvesting  GATCHealth.com Download the transcript here

Today's episode of Out of Patients welcomes Dr Pamela Buchanan, an emergency room physician with over 20 years inside American medicine who refuses to sugarcoat what the job demands and what it destroys. She worked straight through COVID as protocols changed by the day and deaths arrived faster than anyone could process. She logged 80 to 100 hour weeks. She isolated from her family to avoid bringing the virus home. Over time, survival began to feel negotiable.Dr Buchanan speaks openly about burnout as emotional flatline and about physician suicide as a predictable outcome that leadership prefers to ignore. She describes the ER as the catch all for a broken system and explains why chronic care collapses there by design. She shares the reality of trying to access mental health care while still practicing medicine, calling dozens of therapists, getting nowhere, and spending $10,000 to $15,000 out of pocket just to stay alive and functional.Listeners will hear how neurodivergence shaped her career in emergency medicine, how race and trust intersect inside hospital walls, and why doctors are leaving in waves. This conversation carries clarity, anger, humor, and hard earned truth from someone who stayed long enough to name the damage.RELATED LINKSDr Pamela BuchananStrong MedicineDr Pamela Buchanan on LinkedInDr Pamela Buchanan on InstagramEmotional Flatline articleKevinMD essay by Dr Pamela BuchananFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Are you a researcher interested in getting involved in Alzheimer's disease and related dementias (ADRD) clinical trials? The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD, or IMPACT-AD, program brings investigators from around the world together for a week of professional development and education. IMPACT-AD co-directors Dr. Josh Grill and Dr. Rema Raman, as well as faculty member Dr. Maria Carrillo, join the podcast to explain what the program entails, their mission and more. Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, professor, University of California, Irvine (UCI), co-director, IMPACT-AD, Rema Raman, PhD, co-director, IMPACT-AD, director, Biostatistics Section and Recruitment, Engagement, and Retention Section, Alzheimer's Therapeutic Research Institute (ATRI), professor of neurology, University of Southern California (USC), and Maria Carrillo, PhD, chief science officer, medical affairs lead, Alzheimer's Association, co-principal investigator, Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), co-principal investigator, Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) Show Notes Learn more and apply for the 2026 IMPACT-AD program on their website.  Listen to our previous episode with Rema Raman, “Making an IMPACT: Advancing Alzheimer's Disease Clinical Trials Through Workforce Development and Inclusivity,” on our website, Spotify, Apple Podcasts and wherever you listen. Listen to our previous episodes with Josh Grill, “The Case for Disclosing Biomarker Results to Alzheimer's Research Participants” and “Improving Registries and Representation in Alzheimer's Disease Research” on our website. Read more about Dr. Raman in her USC Keck School of Medicine Profile. Read more about Dr. Grill in his UCI faculty profile. Read more about Dr. Carrillo on the Alzheimer's Association website.  Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production. Learn about and pre-order Dr. Chin's book, When Memory Fades: What to Expect at Every Stage, from Early Signs to Full Support for Alzheimer's and Dementia, out June 2, 2026.

Arthur Spalding, TAMM Net, Inc., contract research organization, on FDA Approval, Clinical Trials, and Reimbursement for Medical Devices and Biotech (North Fulton Business Radio, Episode 944) On this episode of North Fulton Business Radio, host John Ray welcomes Arthur Spalding, President of TAMM Net, Inc., a boutique contract research organization that helps biomedical inventors and companies […]

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.What would life look like if Type 1 diabetes suddenly… stopped controlling every decision you make?In this episode of The Healthy Diabetic Podcast, Coach Ken sits down with Katie Beth Hand, a participant in the groundbreaking Eledon clinical trial, which is exploring a potential functional cure for Type 1 diabetes through islet cell transplantation and targeted immune therapy.Katie Beth shares her powerful story—from her unexpected diagnosis at age 26 to becoming Patient 9 in the Eledon trial, a study that has allowed several participants to live without insulin.Together, Ken and Katie explore the emotional reality of diagnosis, the challenges of navigating diabetes as an adult, and the excitement surrounding emerging research that may redefine the future of diabetes treatment.This conversation goes beyond the science. It highlights the lived experience of diabetes and the hope that real progress is finally being made toward a cure.

In this episode of "Next Steps 4 Seniors: Conversations on Aging," host Wendy Jones interviews exercise physiologist Kerri Branca about Parkinson’s disease. They discuss early signs such as loss of smell, constipation, and subtle movement changes, emphasizing the importance of early diagnosis and seeing a movement disorder specialist. Kerri highlights the critical role of exercise, education, and socialization in managing Parkinson’s, shares practical tips for staying active, and reviews treatment options like levodopa. The episode also points listeners to valuable resources, aiming to empower seniors and caregivers with knowledge and support. Every week brings two ways to grow: Tuesdays dive into the physical next steps with real-life guidance for seniors and families, and Fridays uplift the heart with spiritual and emotional next steps—encouragement, faith, and hope for the journey ahead. Today’s episode explores the transformative power of forgiveness and its vital role in experiencing an abundant life as we age. To learn more about Next Steps 4 Seniors, contact us at 248-651-5010 or visit us online at www.nextsteps4seniors.com.Learn more : https://omny.fm/shows/next-steps-4-seniors-with-wendy-jonesSee omnystudio.com/listener for privacy information.

Dr. Alex Marson, MD, PhD, is a professor of medicine at the University of California, San Francisco. We discuss the biology of the immune system and cancer, and everyday choices that can increase or decrease your cancer risk, several of which are surprising but all of which are actionable. We also discuss immunotherapy, including how engineered T-cells can be used to defeat childhood and adult cancers. Dr. Marson explains CRISPR and gene editing to cure diseases, and we address the ethical questions surrounding gene editing in embryos, children and adults. This discussion is for anyone interested in avoiding cancer and/or seeking to understand the science and practical applications of immune- or gene-therapy. Read the show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Alex Marson (00:02:21) Diseases & Current Biological Landscape; AI & Computational Tools (00:05:56) Immune System, Innate vs Adaptive Immune System (00:10:55) Thymus, T Cell Selection; B Cells & Antibodies (00:13:23) Sponsors: BetterHelp & Helix Sleep (00:16:11) Immune System Health, Sleep, Diet; Genes (00:20:56) Childhood Exposure & Allergy Prevention; Autoimmune Reactions (00:25:27) Whole Body Immune Response, Cytokines & Fever; Antibiotics (00:30:51) Cancer; Mutations & Cell Regulation; Smoking, BRCA Mutations, Sunlight (00:38:27) BRAC Mutations, Mutagens, Pesticides (00:42:33) Sponsor: AG1 (00:43:57) X-Rays & Airport Scanners, Carcinogen vs Mutagen, Charred Meat, Food Dye (00:49:34) Immune-Based Cancer Treatment, Checkpoint Inhibitors, CAR T-Cell Therapy (00:59:04) CRISPR, Immunotherapies (01:02:52) Age & Cancer Risk; CAR T-Cells, Targets & Side Effects; Ketogenic Diet (01:08:27) CRISPR Discovery & Mechanism (01:17:06) CRISPR Precision, Risk & Benefit; CRISPR Technology Evolution (01:20:57) Sponsor: LMNT (01:22:17) CRISPR Cell Delivery, Clinical Trials; Treating Early Cancers & Prevention (01:33:47) Liposomes, Engineered Viruses, Lipid Nanoparticles (LNPs), Vaccines (01:39:57) COVID Pandemic & Trust in Science, mRNA Vaccine (01:47:51) Sponsor: Function (01:49:39) Drug Delivery to Cancer, Immunotoxins, T-Cell Engagers; AI Protein Targets (01:55:45) CRISPR Embryo Modification, Ethics; Heritable Gene Editing, Diversity (02:05:42) Deep Sequencing Embryos, Diversity; Overcoming Adversity & Resilience (02:10:44) Upcoming Therapeutics, Autoimmunity & CAR T-Cells, CRISPR & Gene Function (02:17:55) Banking T Cells or iPSCs?, Future of Cell Programming (02:24:41) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Etienne Nichols sits down with Staci Miller, a Human Factors and UX Strategist at GenUX, to demystify the role of human factors (HF) in the medical device regulatory pathway. Staci explains that many companies mistakenly treat HF as a "box-checking" exercise late in development, leading to costly submission delays or rejections when the FDA finds the documentation fails to tell a cohesive safety story.The conversation dives deep into the technical distinctions between a Use-Related Risk Analysis (URRA) and a User Failure Mode and Effects Analysis (uFMEA). Staci provides a framework for deciding which approach fits your product, emphasizing that while large conglomerates with post-market data may lean toward uFMEAs, startups and those with novel devices should prioritize the URRA to effectively map out user interactions without the crutch of existing market data.Finally, Staci addresses one of the most persistent myths in the industry: the idea that clinical trial data can replace human factors validation. She clarifies that while the two can overlap in specific, premeditated circumstances (such as complex implants like aortic valves), they serve entirely different masters—one focused on clinical efficacy and the other on the safety of the user interface across diverse environments.Key Timestamps04:12 – The common disconnect: Integrating Human Factors into ISO 14971 risk management.06:45 – URRA vs. uFMEA: How to choose based on your post-market data and predicate device status.10:30 – The "Definition of Done": Tracking the lifecycle of HF documentation from phase zero to market release.13:15 – System errors vs. Use errors: How to identify root causes during summative studies.18:50 – The "Clinical Trial Myth": Why efficacy data is not the same as usability validation.22:10 – Design Inputs vs. Design Outputs: The "Blueprint and the House" analogy for FDA submissions.25:40 – The impact of the "Use Environment": Testing for movement in ambulances and lighting in radiology suites.Quotes"The FDA doesn't put things out there just to have a good time... If they've made human factors a requirement and you're treating it as a 'suggestion,' you're giving yourself enough rope to hang yourself." - Staci Miller"People are obsessed with the product themselves—the design outputs. But the FDA wants to see the design inputs. They want to see the blueprints of how you built that house, not just the wallpaper." - Staci MillerTakeawaysPremeditation is Key: If you intend to use clinical trial data for HF validation, it must be planned in the protocol from the start; you cannot retroactively claim clinical data satisfies usability requirements.Map User Groups Early: Distinguish clearly between primary and secondary users. Bloating user sets without explaining how or why they engage with the device complicates your risk profile.Environment Matters: Documentation must account for the physical "10,000-foot view," including noise, lighting, and motion (e.g., an ambulance), as these are often where critical use errors occur.HF is Risk Management: Human factors should not live in a silo. It must align with the scales of harm (negligible to catastrophic) defined in ISO 14971 and work in tandem with Quality and Regulatory teams.ReferencesISO 14971: The global standard for the application of risk management to medical devices.FDA Human Factors Guidance: The primary document outlining expectations for usability testing and documentation.Etienne Nichols: LinkedIn ProfileMedTech 101: URRA vs. uFMEAThink of a uFMEA (User Failure Mode and Effects Analysis) like a car manufacturer looking at an old model to see why the brakes failed in the past—it relies on known data to fix specific parts.A URRA (Use-Related Risk Analysis) is like teaching someone to drive a brand-new type of vehicle (like a spaceship) for the first time. Since you don't have "crash data" yet, you have to carefully map out every single step the pilot takes and imagine every possible way they could push the wrong button in the heat of the moment.SponsorsGreenlight Guru: This episode is brought to you by Greenlight Guru, the only quality management platform designed specifically for the medical device industry. Whether you need to manage your QMS to stay compliant with ISO 14971 or streamline your clinical data through their EDC solutions, Greenlight Guru helps you move faster with less risk.Feedback Call-to-ActionWe want to hear from you! Do you have questions about your specific regulatory pathway or a topic you'd like us to cover? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, or suggestions to podcast@greenlight.guru.

In this episode of The Clinical Research Coach, host Leanne Woehlke sits down with Alen Hadzic, Founder and CEO of CT Scan, to explore how data, digital advertising, and AI are reshaping the way patients are enrolled into clinical trials.Coming from a background in consulting, marketing strategy, and lead generation, Alen brings a fresh lens to one of the industry's most persistent challenges—patient recruitment and enrollment. Rather than relying on traditional recruitment models, his company has developed a methodology called Predictive Enrollment Engineering, designed to calculate and optimize cost-per-enrollment using real-world advertising data.Alen shares how CT Scan's patent-pending AI platform, Dyno AI, analyzes millions of dollars in digital advertising performance across dozens of clinical research projects to model enrollment funnels—from ad engagement and qualification to phone contact, eligibility, and final enrollment.During the conversation, Leanne and Alen discuss:Why traditional patient recruitment models often fail to deliver resultsThe hidden friction points that cause patients to drop out of the enrollment funnelHow digital advertising can be used to measure and optimize patient interestThe importance of rapid follow-up and human engagement in improving response ratesHow CT Scan achieves a 65% phone answer rate through immediate outreach and optimized workflowsWhy focusing on cost per enrollment—not cost per lead—changes the entire recruitment strategyAlen also shares his unconventional journey into the clinical trials industry—from early exposure to research through his physician father to a career in consulting and entrepreneurship that ultimately led him to rethink how clinical trials approach patient enrollment.If clinical trial recruitment has ever felt unpredictable, inefficient, or frustrating, this episode offers a data-driven perspective on how AI, marketing science, and operational discipline could transform enrollment into a measurable and predictable process.Tune in to learn how predictive modeling and digital marketing principles may help bring new optimism to clinical trial enrollment.Alen Hadzic is a healthcare technology entrepreneur focused on bringing predictability and operational rigor to clinical trial enrollment. He is the Founder and CEO of CT SCAN™, a company developing systems to remove uncertainty from patient recruitment by engineering enrollment as a measurable process rather than a marketing outcome. His work centers on Predictive Enrollment Engineering™, a methodology that models each stage of the patient journey, from initial awareness through screening and enrollment, using probability-based performance metrics. The company's patent-pending enrollment technology, DYNO Ai™, analyzes operational and advertising data to forecast cost-per-enrollment and reduce study timelines.Hadzic holds a graduate degree from Columbia University and completed a Master's in Innovation and Entrepreneurship at Vlerick Business School, a top-ranked European program in the field. His background combines business strategy, systems thinking, and applied analytics in clinical research operations.Outside of his professional work, he is an active musician who records and performs his own material, playing guitar, drums, and vocals. He approaches both technology and music with a similar philosophy: structured systems can create reliable outcomes, but creativity determines how far those outcomes can be pushed.

Send a textDr. Michael Koren joins Kevin Geddings to discuss the Fatty's Liver's Domino Effect; the concept that a fatty liver can cascade into serious liver problems, including a need for a liver transplant. The duo also discusses the FibroScan, a non-invasive test to assess the level of fatty liver for at-risk individuals. They finish by talking about the importance of early diagnosis to stop the domino effect before it gets out of control.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

The Operation of the Century - Why Total Hip Replacement Keeps Getting Better Interview with Adolph V. Lombardi, Jr., MD, FACS who has performed 38,000+ joint replacements. Topics discussed: Why total hip replacement is considered the “operation of the century” (as described in The Lancet); Modern hips use cementless fixation, advanced ceramics, and highly cross-linked polyethylene, dramatically improving durability to 25–30+ years (or more); Complications like infection, fracture, and dislocation are rare (~1%) and aggressively addressed through patient optimization and surgical advances. Timing now depends on symptoms and quality of life, not just X-rays or age. Emerging innovations, including AI-guided robotics and a promising “reverse hip” design, aim to further improve stability and outcomes. Link to sign up to learn more or enter the ongoing Clinical Trial for this new Technology (https://hipinnovationtechnology.com/) To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Dr. Barbara Paldus is the Founder and CEO of CODEX Labs, the sponsor of this episode.She grew up around Nobel Prize winners, built biotech manufacturing equipment for vaccines and cancer therapeutics, and then sold her company after an 8 year old threatened suicide.Her son's severe eczema pushed her into an unregulated $100,000,000,000 skincare market where parents are told to trust labels that nobody verifies. She explains how corticosteroid ladders leave patients with years long withdrawal, why U.S. ingredient oversight lags Europe, and how chemotherapy destroys the same skin and gut barriers seen in inflammatory disease.The conversation tracks the real stakes behind “clean” marketing: a child's immune system, hospital infections like MRSA, and patients trying to survive treatment without new damage. She also details the research path from Irish medical manuscripts to microbiome science and why sick populations become the only reliable regulators when policy fails.RELATED LINKSBarbara PaldusCodex LabsSekhmet VenturesDr Peter LioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Steve A. Webb, MBBS, MPH, PhD, professor, Royal Perth Hospital, The University of Western Australia discusses Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments with JAMA Statistical Editor Roger J. Lewis, MD, PhD. Related Content: Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments How to Use and Interpret the Results of a Platform Trial

In this episode of The MSing Link Podcast, I tackle the important topic of fake MS cures circulating on social media and give you practical strategies to spot what's real versus AI hype. As a physical therapist specializing in multiple sclerosis, I break down the red and green flags in MS treatment posts, discuss the dangers of misinformation, and share my top resources for fact-checking new therapies or “miracle” cures. Whether you're looking for credible MS treatment updates, research-backed mobility tips, or guidance on evaluating social media claims, this episode will help empower your journey and protect your hope. Tune in for insights, exercises, and expert advice designed to support your strength and independence with MS! Resources mentioned in this episode: PubMed: https://pubmed.ncbi.nlm.nih.gov/ ClinicalTrials.gov: https://clinicaltrials.gov/ Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Summary In this episode, Dr. Faranak Kamangar chats with Dr. James Kilgour about the science behind Kilgour MD's innovative scalp and hair products. They discuss the ingredients, clinical trials, and future developments in hair health and dermatology. Key Topics - Ingredients and science behind Kilgour MD products - Role of dandruff and malassezia in scalp health - Clinical trial evidence for hair growth products - Future R&D and innovations in dermatology and hair care Chapters 00:00 - Introduction and Guest Credibility 01:19 - Personal Experience with Kilgour MD Products 02:25 - Philosophy and Development of Hair Care Products 03:42 - Key Ingredients in Prevention Serum 05:57 - Active Ingredients and Their Effects on Hair Follicles 08:10 - Clinical Trial Evidence for Hair Growth Products 09:11 - Understanding Dandruff and Malassezia's Role 09:46 - Scalp Health and Hair Loss in Menopause 11:58 - Formulation and Efficacy of Anti-Dandruff Treatments 14:20 - Safety and Regulation of Hair Care Ingredients 15:27 - Use of Oils and Botanical Extracts in Hair Care 17:27 - Importance of Clinical Trials in Cosmetic Products 18:24 - Objective Measures in Hair Loss Studies 20:59 - Clinical Significance vs. Perception in Hair Treatments 22:33 - Future R&D and Physician-Led Innovation 25:37 - Upcoming Events and Collaborations 27:15 - Future Directions in Dermatology and Hair Care

Send a textDr. Michael Koren joins Kevin Geddings to discuss an eventful weekend, focusing on the passing of singer, songwriter, and pianist Neil Sedaka. The doctor talks about how a teacher early in the musician's life changed his trajectory and that teachers in general undersand the importance of bringing students up to their potential. The doctor then relates this to clinical research, and how research specialists use all available resources to bring each participant up to their health potential, and how this increases health for that patient and everyone who benefist from advances in medicine.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Episode 2 explores how private‑practice and industry‑run clinical trials bring efficiency, flexibility, and broader patient access to the research landscape. Our guests discuss the financial and scientific motivations behind industry partnerships, the strengths and trade‑offs of private sites, and how these settings support large, fast‑moving studies. Rare‑disease trials, PK designs, and investigator‑initiated research are highlighted as key collaborative touchpoints.This independent medical education program is supported by Incyte.Please click here for a complete list of disclosures.

This episode breaks down the foundations of academic clinical research, from how studies are conceived and funded to how protocols ensure rigor, consistency, and patient safety. Listeners learn about the roles of sponsors, CROs, IRBs, and research teams, as well as the advantages and challenges of conducting trials in academic settings. This independent medical education program is supported by Incyte.Please click here for a complete list of disclosures.

In this final episode, we examine how academia and industry work together to advance research and improve patient outcomes. The conversation highlights real‑world examples of shared data, translational science partnerships, diagnostic insights, and coordinated patient care. Listeners gain a deeper understanding of how combined expertise strengthens clinical trials and expands access to innovative therapies. This independent medical education program is supported by Incyte. Click here for a complete list of disclosures.

In this episode, we dive deep into ASH 2025 updates on myeloid malignancies with Dr. Curtis Lachowiez. From the plenary halls of ASH 2025 to long-term follow-up of Aza/Ven/Gilteritinib, we unpack what the latest evidence means for the future of AML management.1. PARADIGM Trial (Plenary Session, Abstract 6)Fathi A, Perl A, Fell G, et al. Results from PARADIGM – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood 2025;146(Suppl 1):6.https://doi.org/10.1182/blood-2025-6ClinicalTrials.gov: NCT048017972. VICEROY Study – Aza/Ven/Gilteritinib Triplet (Abstract 654)Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy: Interim results from the phase 1/2 VICEROY study. Blood 2025;146(Suppl 1):654.ClinicalTrials.gov: NCT055205673. Long-Term Follow-Up of Aza/Ven/Gilteritinib in FLT3-Mutated AML (Abstract 45)Azevedo RS, et al. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Blood 2025;146(Suppl 1):45.Original publication: Short NJ, Daver N, DiNardo CD, et al. J Clin Oncol 2024;42:1499–1508. https://doi.org/10.1200/JCO.23.01911ClinicalTrials.gov: NCT041404874. PRISM-AML Score (Abstract 453)Lachowiez CA, et al. Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study. Blood 2025;146(Suppl 1):453.Interactive Calculator: https://prism-aml.com5. Additional Studies Referenced in Discussion•       VIALE-A Trial: DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617–629. (NCT02993523)•       VERONA Trial: Randomized study of Aza-Ven vs. Aza vs. placebo in MDS (discussed as a negative study)•       4-Gene Classifier (mPRS): Bataller A, et al. Prognostic risk signature in patients with AML treated with HMA and venetoclax. Blood Adv 2024;8(4):927–935. https://doi.org/10.1182/bloodadvances.2023011757•       LACEWING Trial: Azacitidine plus gilteritinib vs. azacitidine plus placebo in FLT3-mutated AML (discussed as a negative study) 

We love to hear from our listeners. Send us a message.In episode 123 of Cell & Gene: The Podcast, Host Erin Harris talks to Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, about the patient journey in cell therapy trials. They pinpoint key friction points, such as delayed referrals, unpredictable vein-to-vein timelines, and burdensome long-term follow-up, while sharing actionable strategies for simplification. These strategies range from upstream trial design and streamlined consent processes to standardized logistics, hybrid monitoring models, honest risk communication, and engaging patients as true partners in real-world evidence generation.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

In this episode of 10X Growth Strategies, host Arthi Vijayaraghavan sits down with Lakshmi Nair — drug development scientist and genetic engineering researcher — to unpack the science, promise, and responsibility behind CRISPR and gene editing. Drawing from her journey across academia and biomedical research, Lakshmi explains how CRISPR transformed genetic engineering from slow, uncertain experimentation into precise DNA editing — and why that leap could reshape medicine, cancer treatment, and hereditary disease forever. From transgenic models and drug development to the realities of scientific failure and perseverance, the conversation reveals what modern biomedical innovation truly looks like behind the scenes. The episode explores the ethical frontier of gene editing — germline modification, designer traits, disability vs identity, and who gets to decide what should be “fixed” in humans. The discussion also connects CRISPR with AI-driven research, data-intensive clinical trials, and the global scientific ecosystem that turns basic research into life-saving therapies. From biohacking and scientific curiosity to regulation, responsibility, and the future of humanity, this is a thoughtful, deeply grounded conversation on what it means to hold the power to rewrite life itself. A fascinating listen for technologists, policymakers, investors, and anyone curious about where biology, AI, and human evolution intersect. ⸻ 00:00 – Introduction & Lakshmi's Background 02:00 – Why CRISPR Changed Genetic Engineering 06:00 – Scientific Journeys, Curiosity & Upbringing 12:00 – CRISPR Explained for Non-Biologists 18:30 – Medical Applications: Cancer & Genetic Disease 23:30 – Scientific Collaboration & Peer Review 26:30 – Biohacking & Democratizing Biology 30:00 – Gene Editing Ethics & Germline Debate 36:00 – Identity, Disability & Human Choice 40:00 – From Lab Research to Drug Development 45:00 – AI in Clinical Trials & Biomedical Data 50:00 – Future of Gene Editing & Responsibility 54:00 – Closing Reflections

Send a textBen and Daphna review a randomized controlled trial published in The Journal of Pediatrics by Dr. Ariel Salas and colleagues at UAB. The study investigates whether early high-dose vitamin D supplementation (800 IU/day starting day 1) in extremely preterm infants reduces the incidence of Bronchopulmonary Dysplasia (BPD) compared to standard care (starting day 14). The hosts discuss the physiologic rationale linking vitamin D to lung development, the use of impulse oscillometry to measure lung mechanics, and the secondary findings regarding metabolic bone disease. They explore why the "physiologic rationale" doesn't always translate to clinical significance.----Early Vitamin D Supplementation in Infants Born Extremely Preterm and Fed Human Milk: A Randomized Controlled Trial. Salas AA, Argent T, Jeffcoat S, Tucker M, Ashraf AP, Travers CP.J Pediatr. 2025 Dec;287:114754. doi: 10.1016/j.jpeds.2025.114754. Epub 2025 Jul 24.PMID: 40714046 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Is chronic babesiosis finally getting the scientific attention it deserves?In this episode of Integrative Lyme Solutions, Dr. K sits down with Dr. Geoff Dow, CEO & President of Sixty Degrees Pharmaceuticals, to discuss a groundbreaking clinical trial targeting chronic babesiosis — a common and often overlooked Lyme co-infection. Originally developed for malaria prevention, the drug Tafenoquine (brand name Kodatef®) is now being studied for its potential to treat persistent Babesia infections and Lyme-related fatigue.They explore the science behind red blood cell parasites, how Babesia differs from malaria, why chronic babesiosis remains controversial, and what makes this new trial the first FDA-reviewed IND study focused on chronic disease. If you or a loved one struggle with Lyme-related fatigue, relapsing babesiosis, or limited treatment options, this conversation offers cautious optimism and a closer look at the future of targeted therapies.Key Takeaways:0:00 Introduction3:10 From Malaria Drug Development to Lyme Co-Infections6:45 How Babesia Infects Red Blood Cells and Causes Fatigue10:40 Why Chronic Babesiosis Is Still Controversial14:50 No FDA-Approved Drugs Specifically for Babesiosis18:30 New Clinical Trials for Chronic and Relapsing Babesiosis24:00 Measuring Fatigue as a Primary Endpoint in Chronic DiseaseResources Mentioned:Sixty Degrees Pharmaceuticals - https://www.sixtydegreespharma.comKodatef® (Tafenoquine) Information - Available via company website aboveMount Sinai (Clinical Trial Site) - https://www.mountsinai.orgYale Babesiosis Case Series (Referenced Study) - https://medicine.yale.eduMedical Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or replace professional medical advice. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions. _______________________________The Karlfeldt Center offers the most cutting-edge and comprehensive Lyme therapies. To schedule a Free 15-Minute Discovery Call with a Lyme Literate Naturopathic Doctor at The Karlfeldt Center, call 208-338-8902 or email info@TheKarlfeldtCenter.comCheck out Dr. K's Ebook: Breaking Free From Lyme: A Comprehensive Guide to Healing and Recovery here: https://store.thekarlfeldtcenter.com/products/breaking-free-from-lymeUse the code LYMEPODCAST for a 100% off discount!

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Health Affairs' Rob Lott interviews So-Yeon Kang of Georgetown University about her recent paper exploring trends in biopharmaceutical clinical trials after The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs. Order the January 2026 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast

Robert's LinkedIn: https://www.linkedin.com/in/robert-s-goldman/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

From Music to Medicine: Rethinking Clinical Trials, AI, and Real-World Evidence On this episode Gil and Gregg welcome Amir Lahav, MD, ScD, founder and CEO of SkyMedAI and curator of the Digital Health AI Innovation Summit in Boston. Dr. Lahav traces his unlikely path from working musician to Harvard Medical School faculty, Pfizer rare-disease innovator, and now advisor to digital health and life sciences companies. The conversation explores how music-driven neurorehabilitation helped stroke survivors regain motor function, why traditional snapshot-based clinical trials are “embarrassingly wrong” for real-world patients, and how AI and wearables can turn continuous data into earlier detection and more humane care. Lahav also warns about overconfident, under-validated AI and argues that the most successful health companies by 2030 will be those that know when not to use AI. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885 EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017 EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813 Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034 TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031 UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251 Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA II DNR in the Hospital Inadequate Documentation of Unilateral DNR Orders https://jamanetwork.com/journals/jama/fullarticle/2829203 GeriPal Blog Unilateral DNR Orders https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/ III Yet another failure of Targeted Hypothermia 2-Year Follow-Up of TTM2 Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193 TTM2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2100591 IV Good news in HFpEF Evidence ALT-FLOW II Trial https://doi.org/10.1093/ejhf/xuaf016 V GLP-1 as AF drugs Semaglutide as Adjunctive Therapy in Obesity-Related PAF https://doi.org/10.1093/europace/euag018 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Is there evidence that the ketogenic diet can cure schizophrenia?Recent comments from HHS Secretary Robert F. Kennedy Jr. sparked headlines…and controversy. While “cure” isn't the right word, the conversation has brought much-needed attention to an emerging field: metabolic psychiatry.In this video, Dr. Bret Scher breaks down what the science actually shows about ketogenic metabolic therapy as a potential adjunctive treatment for serious mental illness, including schizophrenia, bipolar disorder, and major depressive disorder.You'll learn about:What nutritional ketosis is and why brain energy matters for serious mental illnessHow psychiatric conditions like schizophrenia, bipolar disorder, and major depressive disorder involve underlying metabolic dysfunctionEarly evidence on ketogenic therapy for serious mental illness from Stanford, Edinburgh, and The Ohio State UniversityHow consistent lived experiences aligned with emerging clinical data warrant serious scientific explorationWhat new research is on the wayKetogenic therapy is emerging as a serious metabolic strategy that may expand how we think about treating complex psychiatric conditions. We are now faced with the opportunity to study it rigorously, apply it thoughtfully, and ensure patients have access to every tool that could help.

In this episode, Jess and Sarah welcome Dr. Neil Goldenberg to explore the unique challenges and complexities of conducting pediatric clinical trials. The scientists examine the necessity of multi-center studies, ethical considerations specific to research involving children, and the critical physiological differences between pediatric and adult populations that require distinct research approaches. Dr. Goldenberg shares valuable insights from his research experiences, including the KidsDOTT and COVAC-TP trials, while discussing the essential roles of funding and infrastructure in advancing pediatric research. Throughout the conversation, the experts emphasize the importance of collaboration and advocacy in this field. The episode concludes with an optimistic perspective on the future of pediatric clinical research and its potential to improve health outcomes for children. Watch the conversation on YouTube: https://youtu.be/yqS4b3kqHHM (00:00) Intro & Public Health Update (05:33) What's A Health/Science News Item That Caught Your Attention? (07:34) What Is A Multi-Center Study? (09:35) What Protections Are There For Human Subject Clinical Trials? (13:04) Why Is There A Need For Separate Trials For Children Vs Adults? (17:42) Examples of Dr. Goldenberg's Trials (24:50) What Does It Mean If Pediatric Trials Don't Get Funded? (29:13) Is There Anything We Can Do To Support Pediatric Clinical Trials? (31:51) What's Giving You Hope In Public Health And Science Right Now? https://www.hopkinsmedicine.org/all-childrens-hospital/ https://www.linkedin.com/in/neil-goldenberg-md-phd-59226b63 Disclaimer from Dr. Goldenberg: "The opinions I share during this conversation are my own and do not necessarily reflect the official positions or policies of my employer." ----------------------------------------------------------------------------------------------------------------------- Interested in advertising with us? Please reach out to advertising@airwavemedia.com, with “Unbiased Science” in the subject line. PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional. Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jess and Sarah welcome Dr. Neil Goldenberg to explore the unique challenges and complexities of conducting pediatric clinical trials. The scientists examine the necessity of multi-center studies, ethical considerations specific to research involving children, and the critical physiological differences between pediatric and adult populations that require distinct research approaches. Dr. Goldenberg shares valuable insights from his research experiences, including the KidsDOTT and COVAC-TP trials, while discussing the essential roles of funding and infrastructure in advancing pediatric research. Throughout the conversation, the experts emphasize the importance of collaboration and advocacy in this field. The episode concludes with an optimistic perspective on the future of pediatric clinical research and its potential to improve health outcomes for children. Watch the conversation on YouTube: https://youtu.be/yqS4b3kqHHM (00:00) Intro & Public Health Update (05:33) What's A Health/Science News Item That Caught Your Attention? (07:34) What Is A Multi-Center Study? (09:35) What Protections Are There For Human Subject Clinical Trials? (13:04) Why Is There A Need For Separate Trials For Children Vs Adults? (17:42) Examples of Dr. Goldenberg's Trials (24:50) What Does It Mean If Pediatric Trials Don't Get Funded? (29:13) Is There Anything We Can Do To Support Pediatric Clinical Trials? (31:51) What's Giving You Hope In Public Health And Science Right Now? https://www.hopkinsmedicine.org/all-childrens-hospital/ https://www.linkedin.com/in/neil-goldenberg-md-phd-59226b63 Disclaimer from Dr. Goldenberg: "The opinions I share during this conversation are my own and do not necessarily reflect the official positions or policies of my employer." ----------------------------------------------------------------------------------------------------------------------- Interested in advertising with us? Please reach out to advertising@airwavemedia.com, with “Unbiased Science” in the subject line. PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional. Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tuesday, February 17, 2026 - Week 8   We are flat out, thank you to the team who work full-time on SYNGAP1: VM KAH LP PP & KF.   CLINICAL TRIAL DESIGN We are Angelman-like. (Rett also) https://aesnet.org/abstractslisting/differentiating-key-symptoms-of-angelman-syndrome-as-and-syngap1-via-caregiver-reported-and-us-claims-data-to-understand-differences-between-how-providers-and-caregivers-view-impacts-on-patient-care Dravet or Angelman?  Phase 1/2 is when we try it all.  EEGs and NHS help with this effort.   BIOSAMPLES & EEGs! Biorepository needs more samples.  Check out the list and map here https://combinedbrain.org/roadshow/ and contribute both blood & EEGs.  The data and research we do with these samples is invaluable.  Let us know if you are going, email our CSO@curesyngap1.org.   (Stay tuned for another exciting device study…)   NATURAL HISTORY STUDY Sign up for Citizen Health cureSYNGAP1.org/Citizen and ProMMiS cureSYNGAP1.org/ProMMiS NHS Survey in English: https://curesyngap1.org/SurveyProMMiS & Spanish: https://curesyngap1.org/encuestaProMMiS Latest Pod on NHS: https://youtu.be/7W38uWKBIAw?si=lCrffwMXidmYWz7t   FUNDRAISING - SPRINT4SYNGAP Sprint is April 25 - our calendar page - cureSYNGAP1.org/Sprint - has all the information in the following links: set up your team - cureSYNGAP1.org/Sprint26 resource guide for your event - cureSYNGAP1.org/S4SGuide webinar #99 to help get you started - cureSYNGAP1.org/S4S25   Also, May 28, San Francisco, CA: cureSYNGAP1.org/SF26 Scramble for Syngap - 5th annual on October 3 in S. Carolina cureSYNGAP1.org/Scramble26   PUBMED Pubmed 2026 is at 9! https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date (Remember we had 18 in all of ‘18) Cool connection to #PraderWilli Syndrome. https://www.linkedin.com/posts/graglia_syngap1-praderwilli-autism-share-7429579885985296385-zuIH   ETC - More warriors cureSYNGAP1.org/Warrior - Dr. Donlin-Asp Press Release cureSYNGAP1.org/PR42 see talk here https://www.youtube.com/watch?v=lR8qcZK-9ro - Bravo Sara Driscol and GeneDx https://www.linkedin.com/posts/genedx_beyondawareforrare-ugcPost-7427763511235248129-QPPL?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAD8f4B7JC4TMss45Q8hrsq5kiceI0Z8HE   SOCIAL MATTERS 4,686 LinkedIn.  https://www.linkedin.com/company/curesyngap1 1,520 YouTube.  https://www.youtube.com/@CureSYNGAP1 11.2k Twitter https://twitter.com/cureSYNGAP1 45k Insta https://www.instagram.com/curesyngap1   $CAMP stock is at $3.85 on 17 Feb. ‘26 https://www.google.com/finance/beta/quote/CAMP:NASDAQ   Like and subscribe to this podcast wherever you listen.  https://curesyngap1.org/podcasts/syngap10/ Episode 199 of #Syngap10 #CureSYNGAP1 #Podcast

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send a textIn this episode of Journal Club, Ben and Daphna review a non-inferiority trial from the European Journal of Pediatrics exploring surfactant administration thresholds in preterm neonates. The study, conducted in India, compares a 30% versus 40% FiO2 threshold for babies 26-32 weeks gestational age. The hosts break down the counterintuitive findings regarding respiratory support duration in younger subgroups and discuss the broader implications of using rigid FiO2 heuristics versus individualized patient assessment. They also debate how resource availability influences clinical protocols and the potential benefits of "LISA" (Less Invasive Surfactant Administration) for avoiding intubation.----Higher (40%) versus lower (30%) FiO2 threshold for surfactant administration in preterm neonates between 26 and 32 weeks of gestational age: a non-inferiority randomized controlled trial. Haq MI, Datta V, Bandyopadhyay T, Nangia S, Anand P, Murukesan VM.Eur J Pediatr. 2025 Nov 25;184(12):793. doi: 10.1007/s00431-025-06628-1.PMID: 41288797 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Clinical trials are the gateway to getting life-saving therapies to patients, yet traditional research methods often create barriers that slow progress and limit participation.Our next guest, Dr. Pamela Tenaerts, is tackling this challenge as Chief Medical Officer of Medable.With more than two decades of clinical research experience, including leadership of the Clinical Trials Transformation Initiative, Pamela possesses a unique perspective bridging rigorous science and digital innovation.Driven by a passion to ensure that evidence-based best practices guide how we transform research, Pamela shares Medable's pioneering vision to decentralize clinical trials and meet patients where they are.Join us to discover how Medable's digital platform is accelerating trials across 70 countries, expanding patient access, and getting effective therapies to people faster. Let's go!Episode Highlights:Evidence First: Always research whether a solution actually works before implementing—assumptions can be wrong.One, One, and One: Medable's vision is to start a study in one day, enroll in one day, and complete in one year.Expanding Access: Decentralized trials help rare disease and rural patients participate without traveling to research sites.AI Integration: Medable uses AI to instantly generate patient questionnaires and automate trial workflows.Finding Trials: Patients need easier ways to discover clinical trials that exist for their conditions.About our Guest:Pamela Tenaerts, MD, is Medable's Chief Medical Officer, and aims to drive advancement of decentralized research methodologies with evidence-based best practices. She brings more than two decades of clinical research experience having previously served as Executive Director of the Clinical Trials Transformation Initiative (CTTI), Director of Clinical Programs at Coaxia, Director of the Clinical Research Center at Sarasota Memorial Hospital, and various other research positions. She can be reached at pamela.tenaerts@medable.com.Links Supporting This Episode: Medable Website: CLICK HEREDr. Pamela Tenaerts LinkedIn page: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website:

In the third installment of the Skin Anarchy and Timeline Masterclass, Dr. Ekta Yadav sits down with Dr. Brad Currier, Manager of Clinical Trials at Timeline, for a behind-the-scenes look at what real evidence in longevity science and skincare actually requires.With a foundation in muscle physiology, exercise science, and aging research, Dr. Currier brings a performance-driven lens to longevity — reframing skin not as a cosmetic surface, but as a mitochondria-dense longevity organ, biologically linked to muscle health, metabolic resilience, and cellular energy. The episode explores why mitochondrial function may be one of the most underappreciated drivers of how both skin and the body age.At the center of the conversation is Timeline's research on urolithin A, a postbiotic shown to support mitochondrial renewal. Rather than relying on marketing narratives, Timeline has built its platform on mechanism-first science, translating years of cellular research into human clinical trials — including biopsy-based studies that reveal measurable changes in collagen synthesis and skin structure.Dr. Currier also pulls back the curtain on the truth about clinical claims in beauty — explaining why many “clinically tested” labels lack rigor, how underpowered or biased studies distort results, and what separates meaningful, published human data from perception-based marketing. From wrinkle depth to hydration to barrier function, he outlines how Timeline measures outcomes that reflect real biological change — not just surface-level improvement.The episode ultimately reframes longevity as precision science, not hype — emphasizing the importance of human trials, mitochondrial health, and transparent evidence in an industry flooded with buzzwords.Listen to the full episode of Skin Anarchy to hear Dr. Brad Currier unpack what clinical validation should look like — and why the future of longevity skincare depends on measurable biology, not marketing promises.SHOP TIMELINEDon't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf!Support the show